Chris Mullin is currently the Director of Product Development Strategy at NAMSA where he oversees and manages client partnerships surrounding product development and market commercialization strategies.
Mr. Mullin began his career working on National Institute of Health (NIH)-funded clinical trials, and over the last ten years, he has consulted for medical device organizations throughout the U.S. Asia, and Europe on various clinical trial programs.
A highly sought-after industry expert, Chris has helped hundreds of global manufacturers optimize study design and research, providing proven strategies to address regulatory requirements for market approval and introduction. Chris has worked with multiple innovative technologies across a wide array of therapeutic areas, which has allowed him to provide valuable perspectives to clients on scientific and regulatory challenges – and suggested strategies for success – that impact the advancement of novel medical technology.
Chris has authored multiple peer-reviewed publications a book chapter on clinical study design for translational research, and serves as a journal editor. Chris holds a Master’s Degrees in Biostatistics from the University of Minnesota. He earned his Bachelor’s Degree at the University of Wisconsin-Madison in Mathematics.
